RELMADA THERAPEUTICS, INC. Employee Stock Ownership Plan (ESOP), Compensation Expense
RELMADA THERAPEUTICS, INC. (RLMD) reported Employee Stock Ownership Plan (ESOP), Compensation Expense of $62.80 thousand for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense · last filed 2022-11-10
- RELMADA THERAPEUTICS, INC. employee stock ownership plan (esop), compensation expense for the quarter ending 2022-06-30 was $31.20K, a 18.92% decline year-over-year.
- RELMADA THERAPEUTICS, INC. employee stock ownership plan (esop), compensation expense for the quarter ending 2022-03-31 was $31.60K, a 21.63% decline year-over-year.
- RELMADA THERAPEUTICS, INC. employee stock ownership plan (esop), compensation expense for the quarter ending 2021-12-31 was $11.81K, a 63.31% decline year-over-year.
- RELMADA THERAPEUTICS, INC. employee stock ownership plan (esop), compensation expense for the quarter ending 2021-09-30 was $22.30K, a 27.36% decline year-over-year.
- RELMADA THERAPEUTICS, INC. employee stock ownership plan (esop), compensation expense for fiscal 2021 was $112.91K, a 24.50% increase from fiscal 2020.
- RELMADA THERAPEUTICS, INC. employee stock ownership plan (esop), compensation expense for fiscal 2020 was $90.69K.
| Period end | Employee Stock Ownership Plan (ESOP), Compensation Expense 3 month | Employee Stock Ownership Plan (ESOP), Compensation Expense 6 month | Employee Stock Ownership Plan (ESOP), Compensation Expense 9 month | Employee Stock Ownership Plan (ESOP), Compensation Expense 12 month |
|---|---|---|---|---|
| 2022-06-30 | $31.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $62.80K 10-Q · filed 2022-08-11 | $74.61K derived: sum of 3 quarters · filed 2022-08-11 | $96.91K derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-03-31 | $31.60K 10-Q · filed 2022-05-05 | $43.41K derived: sum of 2 quarters · filed 2022-05-05 | $65.71K derived: sum of 3 quarters · filed 2022-11-10 | $104.19K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-12-31 | $11.81K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $34.11K derived: sum of 2 quarters · filed 2022-11-10 | $72.59K derived: sum of 3 quarters · filed 2022-11-10 | $112.91K 10-K · filed 2022-03-25 |
| 2021-09-30 | $22.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $60.78K derived: sum of 2 quarters · filed 2022-11-10 | $101.10K 10-Q · filed 2022-11-10 | $133.29K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $38.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $78.80K 10-Q · filed 2022-08-11 | $110.99K derived: sum of 3 quarters · filed 2022-08-11 | $141.69K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $40.32K 10-Q · filed 2022-05-05 | $72.51K derived: sum of 2 quarters · filed 2022-05-05 | $103.21K derived: sum of 3 quarters · filed 2022-05-05 | |
| 2020-12-31 | $32.19K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $62.89K derived: sum of 2 quarters · filed 2022-03-25 | $90.69K 10-K · filed 2022-03-25 | |
| 2020-09-30 | $30.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $58.50K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $27.80K 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |